CO MYCOPHENOLATE TABLET

Country: Канада

Језик: Енглески

Извор: Health Canada

Активни састојак:

MYCOPHENOLATE MOFETIL

Доступно од:

COBALT PHARMACEUTICALS COMPANY

АТЦ код:

L04AA06

INN (Међународно име):

MYCOPHENOLIC ACID

Дозирање:

500MG

Фармацеутски облик:

TABLET

Састав:

MYCOPHENOLATE MOFETIL 500MG

Пут администрације:

ORAL

Јединице у пакету:

50/100

Тип рецептора:

Prescription

Терапеутска област:

IMMUNOSUPPRESSIVE AGENTS

Резиме производа:

Active ingredient group (AIG) number: 0128158002; AHFS:

Статус ауторизације:

CANCELLED POST MARKET

Датум одобрења:

2018-05-07

Карактеристике производа

_ _
_ _
_Page 1 of 55_
PRODUCT MONOGRAPH
PR
_CO_ MYCOPHENOLATE
Mycophenolate Mofetil Tablets USP
500 mg
Immunosuppressive Agent
Cobalt Pharmaceuticals Company
6500 Kitimat Road
Mississauga, Ontario
L5N 2B8
SUBMISSION CONTROL NO: 168316
Date of Revision:
October 16, 2013
_ _
_ _
_Page 2 of 55_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
7
DRUG INTERACTIONS
.................................................................................................
15
DOSAGE AND ADMINISTRATION
.............................................................................
18
OVERDOSAGE
...............................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 20
STORAGE AND STABILITY
.........................................................................................
27
SPECIAL HANDLING INSTRUCTIONS
......................................................................
27
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 27
PART II: SCIENTIFIC INFORMATION
..............................................................................
28
PHARMACEUTICAL INFORMATION
.........................................................................
28
CLINICAL TRIALS
.........................................................................................................
29
DETAILED PHARMACOLOGY
.............................................................................